essential thrombocythaemia

essential thrombocythaemia

A rare blood disorder featuring an excess of blood platelets with the increased risk of clotting of blood within the blood vessels (thrombosis). The cause is unknown.
Mentioned in ?
References in periodicals archive ?
Association of V617F Jak2 mutation with the risk of thrombosis among patients with essential thrombocythaemia or idiopathic myelofibrosis: a systematic review.
Ph chromosome-negative neoplasms include polycythaemia vera (PV), essential thrombocythaemia (ET) and primary myelofibrosis (PMF), whereas chronic myeloid leukaemia (CML) comprises Ph chromosome-positive neoplasms.
Pt is diagnosed as MPD: Essential Thrombocythaemia.
Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study.
Patients and Methods: Ninety three consecutive patients of Polycythaemia vera (PV), Essential thrombocythaemia (ET) and Idiopathic myelofibrosis (IMF) diagnosed by the conventional haematological criteria were included in the study.
Epidemiology of the myeloproliferative disorders: essential thrombocythaemia, polycythaemia vera and idiopathic myelofibrosis.
Increased risk for vascular complications in PRV-1 positive patients with essential thrombocythaemia.
AGRYLIN is a treatment for essential thrombocythaemia (ET), a chronic disorder of bone marrow, which is associated with the increased production of blood platelets.
QA DISTANT relative has been diagnosed with a condition called essential thrombocythaemia and has a platelet count of 1000.
Shire Pharmaceuticals markets Agrylin for the treatment of thrombocytosis and essential thrombocythaemia.

Full browser ?